Asia Pacific Biomaterials Market by Type (Metallic [Gold, Magnesium], Ceramic [Aluminum Oxide, Carbon], Polymer [Polyethylene, Polyester], Natural [Hyaluronic acid, Collagen, Gelatin]), Application (Orthopedic, Dental, CVD, Ophthalmology) - Forecast to 2030

icon1
USD 15.12 BN
MARKET SIZE, 2030
icon2
CAGR 7.8%
(2025-2030)
icon3
450
REPORT PAGES
icon4
550
MARKET TABLES

OVERVIEW

asia-pacific-biomaterials-market Overview

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

The Asia Pacific biomaterials market is projected to reach USD 15.12 billion by 2030 from USD 10.39 billion in 2025, at a CAGR of 7.8% from 2025 to 2030. Biomaterials are substances designed to interact with biological systems for medical purposes. These materials are designed to be compatible with living tissues and can be used in various medical applications, such as implants, prosthetics, drug delivery systems, and tissue engineering.

KEY TAKEAWAYS

  • BY REGION
    China is projected to register the highest growth rate of 8.4% in the Asia Pacific biomaterials market during the forecast period.
  • BY type
    By type, the metallic biomaterials segment is projected to register the highest CAGR of 8.2% during the forecast period.
  • BY Application
    By application, the orthopedics segment is projected to register the highest CAGR of 8.4% in the Asia Pacific biomaterials market during the forecast period.
  • COMPETITIVE LANDSCAPE
    BASF SE, Celanese Corporation, and Carpenter Technology were identified as star players in the Asia Pacific biomaterials market, given their strong market share and extensive product footprint.
  • COMPETITIVE LANDSCAPE
    Evergen and Jellatech have distinguished themselves among startups and SMEs by securing strong footholds in specialized niche areas, underscoring their potential as emerging market leaders.

The Asia Pacific biomaterials market is expanding rapidly, driven by a surge in joint replacement, spine, and trauma procedures, as well as the growing adoption of advanced implant materials. The rising geriatric and osteoarthritis populations, expanding medical tourism hubs, and increasing investment in regenerative medicine and customized 3D-printed implants are further accelerating demand for high-performance orthopedic biomaterials across the region.

TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS

The Asia Pacific biomaterials market is currently experiencing a phase of innovation and rapid adoption. Health systems in China, India, Japan, South Korea, and countries in Southeast Asia are witnessing advancements in biomaterials development and regulation. This progress aligns with emerging trends in precision orthopedics, tissue-engineered therapies, and regenerative medicine. In the Asia Pacific region, the use of bioresorbable polymers, bioactive ceramics, and other chemical substances is increasing among hospitals and orthopedic centers. These materials facilitate the use of scaffolds made from collagen or hydrogels, which promote faster healing, reduce the need for hardware removal surgeries, and align with minimally invasive and outpatient care approaches. Governments and regulatory bodies are encouraging local manufacturing, the development of 3D-printed personalized implants, and public-private research and development programs. These initiatives help shorten approval timelines and promote the adoption of automation-friendly, clinically validated biomaterial platforms tailored to the needs of regional patient populations.

asia-pacific-biomaterials-market Disruptions

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

MARKET DYNAMICS

Drivers
Impact
Level
  • Rapid expansion of healthcare infrastructure and increasing healthcare expenditure
  • Rising prevalence of chronic diseases, trauma, and age-related conditions in the region
RESTRAINTS
Impact
Level
  • Limited reimbursement policies and inconsistent regulatory frameworks
OPPORTUNITIES
Impact
Level
  • Expanding demand for bioresorbable polymers and advanced polymeric biomaterials
CHALLENGES
Impact
Level
  • Ensuring consistent product quality and biocompatibility across varied production standards

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

Driver: Rapid expansion of healthcare infrastructure and increasing healthcare expenditure

The rapid expansion of healthcare infrastructure across the Asia Pacific region, along with rising healthcare expenditure, is supporting greater adoption of biomaterials. Governments and private players are investing in hospitals, surgical facilities, and advanced medical technologies, which is increasing the use of biomaterials in implants, devices, and regenerative therapies.

Restraint: Limited reimbursement policies and inconsistent regulatory frameworks

Limited reimbursement coverage and uneven regulatory frameworks in several Asia Pacific countries restrict the adoption of advanced biomaterials. Differences in approval timelines, pricing controls, and healthcare policies create challenges for manufacturers trying to introduce high-value biomaterial products across the region.

Opportunity: Expanding demand for bioresorbable polymers and advanced polymeric biomaterials

The growing demand for bioresorbable polymers and advanced polymeric biomaterials presents significant growth opportunities in the Asia Pacific region. These materials are increasingly utilized in minimally invasive procedures, temporary implants, and tissue repair applications, aligning well with the focus on cost-effective and patient-friendly treatments.

Challenges : Ensuring consistent product quality and biocompatibility across varied production standards

Ensuring consistent product quality and biocompatibility remains a key challenge due to the varied manufacturing standards and regulatory requirements across the Asia Pacific markets. Suppliers must invest in quality control, compliance, and clinical validation to maintain reliability and acceptance of biomaterial products.

ASIA PACIFIC BIOMATERIALS MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES

COMPANY USE CASE DESCRIPTION BENEFITS
PMMA bone cements and UHMWPE components used in joint replacement and trauma fixation procedures in rapidly growing orthopedic markets. Provides strong fixation, durability, and reliable load distribution, supporting rising volumes of hip and knee replacement surgeries.
Celanese supplies medical-grade engineered polymers (such as UHMWPE, PEEK-based materials, and specialty acetals) to orthopedic and medical device manufacturers across China, Japan, South Korea, and India for joint replacement components, surgical instruments, and implant housings. Ensures high mechanical strength, wear resistance, and biocompatibility, supports reliable implant performance, and enables cost-efficient large-scale manufacturing.

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

MARKET ECOSYSTEM

The Asia Pacific biomaterials market is a collaborative ecosystem where material companies, device manufacturers, biotech firms, institutions, and healthcare professionals work together to develop and implement biomaterials in the healthcare sector. Companies in the region supply a variety of biomaterials, including polymers, metals, ceramics, and natural substances. Contract research organizations (CROs), contract development and manufacturing organizations (CDMOs), and institutions in countries such as China, Japan, South Korea, India, and Australia support the preclinical and clinical development stages, as well as the scale-up process for these biomaterials. Ultimately, healthcare institutions and providers in the Asia Pacific region utilize the developed biomaterials, benefiting from supportive regulations and reimbursement schemes.

asia-pacific-biomaterials-market Ecosystem

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

MARKET SEGMENTS

asia-pacific-biomaterials-market Segments

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

Asia Pacific Biomaterials Market, by Type

Metallic biomaterials dominated the market in 2024, with metals being the backbone of most medical devices used daily in hospitals and clinics. This is due to their strength, durability, and proven performance, making them preferred for cardiovascular stents and dental implants.

Asia Pacific Biomaterials Market, by Application

Orthopedics represented the largest segment of the Asia Pacific biomaterials market. The increasing prevalence of bone and joint disorders has propelled this segment to the forefront in the region. Factors such as an aging population, a growing number of patients with osteoarthritis and osteoporosis, as well as road and sports accidents, are driving the demand for joint replacements, trauma implants, and spinal devices.

REGION

China to be fastest-growing country in market during forecast period

China is the fastest-growing country in the Asia Pacific biomaterials market, driven by its rapidly expanding hospital network, increasing number of surgical procedures, and strong government support for medical research and development. The demand for orthopedic, cardiovascular, and dental surgeries is increasing, along with the production of medical devices and biomaterials in China. Additionally, significant investment in research and development for regenerative medicine, combined with a large patient base for clinical research studies, is facilitating the swift transition of biomaterials from research and development to clinical practice.

asia-pacific-biomaterials-market Region

ASIA PACIFIC BIOMATERIALS MARKET: COMPANY EVALUATION MATRIX

BASF, recognized as a leading player in the polymer segment of the Asia Pacific biomaterials market, offers a diverse portfolio that includes medical-grade plastics, superabsorbent polymers, and specialty materials for medical devices. The company boasts a strong manufacturing base in the Asia Pacific region and collaborates with medical technology companies and hygiene product providers in China, Japan, South Korea, and India. Another significant player in the Asia Pacific market is Mitsubishi Chemical Group Corporation, identified as an emerging leader. The company is strengthening its position by introducing advanced polymers, bioresorbable materials, and specialty resins designed for use in orthopedic, cardiovascular, and dental devices.

asia-pacific-biomaterials-market Evaluation Metrics

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

KEY MARKET PLAYERS

MARKET SCOPE

REPORT METRIC DETAILS
Market Size in 2024 (Value) USD 9.66 Billion
Market Forecast in 2030 (Value) USD 15.12 Billion
Growth Rate CAGR of 7.8% from 2025-2030
Years Considered 2023-2030
Base Year 2024
Forecast Period 2025-2030
Units Considered Value (USD Million)
Report Coverage Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, and Trends
Segments Covered
  • By Type:
    • Metallic Biomaterials
    • Polymeric Biomaterials
    • Ceramic Biomaterials
    • Natural Biomaterials
  • By Application:
    • Orthopedic
    • Cardiovascular
    • Dental
    • Plastic Surgery
    • Urinary
    • Wound Healing
    • Tissue Engineering
    • Ophthalmology
    • Neurological/Central Nervous System
    • Other Applications
Countries Covered China, Japan, India, South Korea, Australia, and Rest of Asia Pacific

WHAT IS IN IT FOR YOU: ASIA PACIFIC BIOMATERIALS MARKET REPORT CONTENT GUIDE

asia-pacific-biomaterials-market Content Guide

DELIVERED CUSTOMIZATIONS

We have successfully delivered the following deep-dive customizations:

CLIENT REQUEST CUSTOMIZATION DELIVERED VALUE ADDS
Understanding demand patterns for biomaterials across Asia Pacific healthcare systems Assessed biomaterial usage trends across key Asia Pacific countries (China, Japan, India, South Korea, and Southeast Asia), highlighting differences in adoption of metallic, polymeric, ceramic, and natural biomaterials across orthopedic, dental, cardiovascular, and wound-care applications Helps clients align product portfolios with country-specific demand drivers, reimbursement maturity, and procedure volumes
Identifying local manufacturing and sourcing opportunities Mapped regional biomaterials suppliers, CDMOs, and device manufacturers across China, Japan, South Korea, and India, with insights into polymer compounding, implant machining, ceramic processing, and medical-grade raw material supply Supports localization strategies, reduces supply-chain risk, lowers production costs, and improves speed-to-market

RECENT DEVELOPMENTS

  • December 2024 : Mitsubishi Chemical Group’s MediTECH and ChronoFlex materials, designed for long-term implant use and advanced orthopedic applications, were highlighted in the company’s medical-device solutions portfolio, demonstrating enhanced biological compatibility and mechanical durability for surgical implants such as artificial joints and spinal components.
  • November 2021 : Celanese Corporation and Mitsubishi Chemical Advanced Materials (MCAM) announced a collaboration to develop mechanical recycling solutions for polyoxymethylene (POM), also known as acetal copolymer. The partnership aims to convert both post-industrial and post-consumer POM waste into recycled feedstocks to create new formulations that maintain high quality and performance.

 

Table of Contents

Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.

TITLE
PAGE NO
1
INTRODUCTION
 
 
 
 
15
2
EXECUTIVE SUMMARY
 
 
 
 
 
3
PREMIUM INSIGHTS
 
 
 
 
 
4
MARKET OVERVIEW
Presents a concise view of industry direction, strategic priorities, and key indicators influencing market momentum.
 
 
 
 
 
 
4.1
INTRODUCTION
 
 
 
 
 
4.2
MARKET DYNAMICS
 
 
 
 
 
 
4.2.1
DRIVERS
 
 
 
 
 
4.2.2
RESTRAINTS
 
 
 
 
 
4.2.3
OPPORTUNITIES
 
 
 
 
 
4.2.4
CHALLENGES
 
 
 
 
4.3
UNMET NEEDS AND WHITE SPACES
 
 
 
 
 
4.4
INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES
 
 
 
 
 
4.5
STRATEGIC MOVES BY TIER-1/2/3 PLAYERS
 
 
 
 
5
INDUSTRY TRENDS
Maps the market evolution with focus on trend catalysts, risk factors, and growth opportunities across segments.
 
 
 
 
 
 
5.1
PORTER’S FIVE FORCES ANALYSIS
 
 
 
 
 
5.2
MACROECONOMIC OUTLOOK
 
 
 
 
 
 
5.2.1
INTRODUCTION
 
 
 
 
 
5.2.2
GDP TRENDS AND FORECAST
 
 
 
 
 
5.2.3
TRENDS IN ASIA PACIFIC BIOMATERIALS MARKET
 
 
 
 
5.3
VALUE CHAIN ANALYSIS
 
 
 
 
 
 
5.4
ECOSYSTEM ANALYSIS
 
 
 
 
 
 
5.5
PRICING ANALYSIS
 
 
 
 
 
 
 
5.5.1
AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY PRODUCT, 2022–2024
 
 
 
 
 
5.5.2
AVERAGE SELLING PRICE TREND, BY COUNTRY,
 
 
 
 
5.6
TRADE ANALYSIS
 
 
 
 
 
 
 
5.6.1
IMPORT SCENARIO (HS CODE 7221)
 
 
 
 
 
5.6.2
EXPORT SCENARIO (HS CODE 7221)
 
 
 
 
5.7
KEY CONFERENCES AND EVENTS, 2025–2026
 
 
 
 
 
5.8
TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
 
 
 
 
 
5.9
INVESTMENT AND FUNDING SCENARIO
 
 
 
 
 
 
5.9.1
VC/PRIVATE EQUITY INVESTMENT TRENDS & STARTUP LANDSCAPE
 
 
 
 
5.10
IMPACT OF 2025 US TARIFF – ASIA PACIFIC BIOMATERIALS MARKET
 
 
 
 
 
 
 
5.10.2
INTRODUCTION
 
 
 
 
 
5.10.2
KEY TARIFF RATES
 
 
 
 
 
5.10.3
PRICE IMPACT ANALYSIS
 
 
 
 
 
5.10.4
IMPACT ON COUNTRIES
 
 
 
 
 
5.11.5
IMPACT ON END-USE INDUSTRIES
 
 
 
6
TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS
 
 
 
 
 
 
6.1
KEY EMERGING TECHNOLOGIES
 
 
 
 
 
 
6.1.1
PRECISION TECHNOLOGY
 
 
 
 
 
6.1.2
BIOMIMETICS
 
 
 
 
6.2
ADJACENT TECHNOLOGIES
 
 
 
 
 
 
6.2.1
3D BIOPRINTING
 
 
 
 
 
6.2.1
ELECTROSPINNING
 
 
 
 
6.3
TECHNOLOGY/PRODUCT ROADMAP
 
 
 
 
 
6.4
PATENT ANALYSIS
 
 
 
 
 
 
6.5
FUTURE APPLICATIONS
 
 
 
 
 
6.6
IMPACT OF AI/GEN AI ON ASIA PACIFIC BIOMATERIALS MARKET
 
 
 
 
 
 
 
6.6.1
TOP USE CASES AND MARKET POTENTIAL
 
 
 
 
 
6.6.2
CASE STUDIES OF AI IMPLEMENTATION IN ASIA PACIFIC BIOMATERIALS MARKET
 
 
 
 
 
6.6.3
INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS
 
 
 
 
 
6.6.4
CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN ASIA PACIFIC BIOMATERIALS MARKET
 
 
 
7
SUSTAINABILITY AND REGULATORY LANDSCAPE
 
 
 
 
 
 
7.1
REGIONAL REGULATIONS AND COMPLIANCE
 
 
 
 
 
 
7.1.1
REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
 
7.1.2
INDUSTRY STANDARDS
 
 
 
 
7.2
SUSTAINABILITY IMPACT AND REGULATORY POLICY INITIATIVES
 
 
 
 
 
7.3
CERTIFICATIONS, LABELING, & ECO-STANDARDS
 
 
 
 
8
CUSTOMER LANDSCAPE & BUYER BEHAVIOR
 
 
 
 
 
 
8.1
DECISION-MAKING PROCESS
 
 
 
 
 
8.2
BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA
 
 
 
 
 
8.3
ADOPTION BARRIERS & INTERNAL CHALLENGES
 
 
 
 
 
8.4
UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
 
 
 
 
 
8.5
MARKET PROFITABILITY
 
 
 
 
9
ASIA PACIFIC BIOMATERIALS MARKET, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
COMPARATIVE ASSESSMENT OF KEY TYPES, THEIR MARKET POTENTIAL, AND REVENUE TRENDS
 
 
 
 
 
 
9.1
INTRODUCTION
 
 
 
 
 
9.2
METALLIC BIOMATERIALS
 
 
 
 
 
 
9.2.1
STAINLESS STEEL
 
 
 
 
 
9.2.2
TITANIUM & TITANIUM ALLOYS
 
 
 
 
 
9.2.3
COBALT-CHROME ALLOYS
 
 
 
 
 
9.2.4
SILVER
 
 
 
 
 
9.2.5
GOLD
 
 
 
 
 
9.2.6
MAGNESIUM
 
 
 
 
 
9.2.7
OTHER METALLIC BIOMATERIALS
 
 
 
 
9.3
POLYMERIC BIOMATERIALS
 
 
 
 
 
 
9.3.1
POLYMETHYLMETHACRYLATE (PMMA)
 
 
 
 
 
9.3.2
POLYETHYLENE
 
 
 
 
 
9.3.3
POLYESTER
 
 
 
 
 
9.3.4
POLYVINYLCHLORIDE
 
 
 
 
 
9.3.5
SILICONE RUBBER
 
 
 
 
 
9.3.6
NYLON
 
 
 
 
 
9.3.7
POLYETHERETHERKETONE (PEEK)
 
 
 
 
 
9.3.8
OTHER POLYMERIC BIOMATERIALS
 
 
 
 
9.4
CERAMIC BIOMATERIALS
 
 
 
 
 
 
9.4.1
CALCIUM PHOSPHATE
 
 
 
 
 
9.4.2
ZIRCONIA
 
 
 
 
 
9.4.3
ALUMINUM OXIDE
 
 
 
 
 
9.4.4
CALCIUM SULFATE
 
 
 
 
 
9.4.5
CARBON
 
 
 
 
 
9.4.6
GLASS
 
 
 
 
9.5
NATURAL BIOMATERIALS
 
 
 
 
 
 
9.5.1
HYALURONIC ACID
 
 
 
 
 
9.5.2
COLLAGEN
 
 
 
 
 
9.5.3
FIBRIN
 
 
 
 
 
9.5.4
CELLULOSE
 
 
 
 
 
9.5.5
CHITIN
 
 
 
 
 
9.5.6
ALGINATE
 
 
 
 
 
9.5.7
GELATIN
 
 
 
 
 
9.5.8
CHITOSAN
 
 
 
 
 
9.5.9
SILK
 
 
 
 
 
9.5.10
OTHER NATURAL BIOMATERIALS
 
 
 
11
ASIA PACIFIC BIOMATERIALS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
APPLICATION-WISE DEMAND POTENTIAL AND GROWTH PATHWAYS ADOPTION IN DIVERSE INDUSTRIES
 
 
 
 
 
 
11.1
INTRODUCTION
 
 
 
 
 
11.2
CARDIOVASCULAR
 
 
 
 
 
 
11.2.1
CATHETERS
 
 
 
 
 
11.2.2
STENTS
 
 
 
 
 
11.2.3
IMPLANTABLE CARDIAC DEFIBRILLATORS
 
 
 
 
 
11.2.4
PACEMAKERS
 
 
 
 
 
11.2.5
SENSORS
 
 
 
 
 
11.2.6
HEART VALVES
 
 
 
 
 
11.2.7
VASCULAR GRAFTS
 
 
 
 
 
11.2.8
GUIDEWIRES
 
 
 
 
 
11.2.9
OTHER PRODUCTS
 
 
 
 
11.3
ORTHOPEDIC
 
 
 
 
 
 
11.3.1
JOINT REPLACEMENT
 
 
 
 
 
 
11.3.1.1
KNEE REPLACEMENT
 
 
 
 
 
11.3.1.2
HIP REPLACEMENT
 
 
 
 
 
11.3.1.3
SHOULDER REPLACEMENTS
 
 
 
 
 
11.3.1.4
OTHER JOINT REPLACEMENT APPLICATIONS
 
 
 
 
11.3.2
SPINE SURGERIES
 
 
 
 
 
 
11.3.2.1
SPINAL FUSION
 
 
 
 
 
11.3.2.2
MINIMALLY INVASIVE FUSION
 
 
 
 
 
11.3.2.3
MOTION PRESERVATION & DYNAMIC STABILIZATION
 
 
 
 
 
 
11.3.2.3.1
PEDICLE-BASED ROD SYSTEMS
 
 
 
 
 
11.3.2.3.2
INTERSPINOUS SPACERS
 
 
 
 
 
11.3.2.3.3
ARTIFICIAL DISCS
 
 
 
11.3.3
BIORESORBABLE TISSUE FIXATION
 
 
 
 
 
 
11.3.3.1
SUTURE ANCHORS
 
 
 
 
 
11.3.3.2
INTERFERENCE SCREWS
 
 
 
 
 
11.3.3.3
MENISCAL REPAIR TACKS
 
 
 
 
 
11.3.3.4
MESHES
 
 
 
 
11.3.4
ORTHOBIOLOGICS
 
 
 
 
 
11.3.5
FRACTURE FIXATION
 
 
 
 
 
 
11.3.5.1
BONE PLATES
 
 
 
 
 
11.3.5.2
SCREWS
 
 
 
 
 
11.3.5.3
PINS
 
 
 
 
 
11.3.5.4
RODS
 
 
 
 
 
11.3.5.5
WIRES
 
 
 
11.4
OPHTHALMOLOGY
 
 
 
 
 
 
11.4.1
CONTACT LENSES
 
 
 
 
 
11.4.2
INTRAOCULAR LENSES
 
 
 
 
 
11.4.3
FUNCTIONAL REPLACEMENTS OF OCULAR TISSUES
 
 
 
 
 
11.4.4
SYNTHETIC CORNEAS
 
 
 
 
 
11.4.5
OTHER OPHTHALMOLOGY APPLICATIONS
 
 
 
 
11.5
DENTAL
 
 
 
 
 
 
11.5.1
DENTAL IMPLANTS
 
 
 
 
 
11.5.2
DENTAL BONE GRAFTS & SUBSTITUTES
 
 
 
 
 
11.5.3
DENTAL MEMBRANES
 
 
 
 
 
11.5.4
TISSUE REGENERATION MATERIALS
 
 
 
 
11.6
PLASTIC SURGERY
 
 
 
 
 
 
11.6.1
SOFT-TISSUE FILLERS
 
 
 
 
 
11.6.2
CRANIOFACIAL SURGERY
 
 
 
 
 
11.6.3
FACIAL WRINKLE TREATMENT
 
 
 
 
 
11.6.4
BIOENGINEERED SKINS
 
 
 
 
 
11.6.5
PERIPHERAL NERVE REPAIR
 
 
 
 
 
11.6.6
ACELLULAR DERMAL MATRICES
 
 
 
 
11.7
WOUND HEALING
 
 
 
 
 
 
11.7.1
WOUND CLOSURE DEVICES
 
 
 
 
 
 
11.7.1.1
SUTURES
 
 
 
 
 
11.7.1.2
STAPLES
 
 
 
 
11.7.2
INTERNAL TISSUE SEALANTS
 
 
 
 
 
11.7.3
SURGICAL HEMOSTATS
 
 
 
 
 
11.7.4
ADHESION BARRIERS
 
 
 
 
 
11.7.5
HERNIA MESHES
 
 
 
 
 
11.7.6
SKIN SUBSTITUTES
 
 
 
 
11.8
TISSUE ENGINEERING
 
 
 
 
 
 
11.8.1
SCAFFOLDS FOR BIOMATERIALS
 
 
 
 
 
11.8.2
NANOMATERIALS FOR BIOSENSING
 
 
 
 
 
11.8.3
TAILORING OF INORGANIC NANOPARTICLES
 
 
 
 
11.9
NEUROLOGICAL/CENTRAL NERVOUS SYSTEM APPLICATIONS
 
 
 
 
 
 
11.9.1
SHUNTING SYSTEMS
 
 
 
 
 
11.9.2
CORTICAL NEURAL PROSTHETICS
 
 
 
 
 
11.9.3
HYDROGEL SCAFFOLDS FOR CNS REPAIR
 
 
 
 
 
11.9.4
NEURAL STEM CELL ENCAPSULATION
 
 
 
 
11.10
URINARY APPLICATIONS
 
 
 
 
 
 
11.10.1
URINARY CATHETERS
 
 
 
 
 
11.10.2
URETHRAL STENTS
 
 
 
 
 
11.10.3
OTHERS
 
 
 
 
11.11
OTHER APPLICATIONS
 
 
 
 
 
 
11.11.1
DRUG DELIVERY SYSTEMS
 
 
 
 
 
11.11.2
GASTROINTESTINAL APPLICATIONS
 
 
 
 
 
11.11.3
BARIATRIC SURGERY
 
 
 
12
ASIA PACIFIC BIOMATERIALS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
ASSESSMENT OF GROWTH PATTERNS, INDUSTRY FORCES, REGULATORY LANDSCAPE, AND MARKET POTENTIAL ACROSS KEY COUNTRIES
 
 
 
 
 
 
12.1
INTRODUCTION
 
 
 
 
 
12.2
ASIA PACIFIC
 
 
 
 
 
 
12.2.1
CHINA
 
 
 
 
 
12.2.2
JAPAN
 
 
 
 
 
12.2.3
INDIA
 
 
 
 
 
12.2.4
SOUTH KOREA
 
 
 
 
 
12.2.5
AUSTRALIA
 
 
 
 
 
12.2.6
REST OF ASIA PACIFIC
 
 
 
 
 
12.2.7
MACROECONOMIC OUTLOOK OF ASIA PACIFIC
 
 
 
13
COMPETITIVE LANDSCAPE
 
 
 
 
 
 
STRATEGIC ASSESSMENT OF LEADING PLAYERS, MARKET SHARE, REVENUE ANALYSIS, COMPANY POSITIONING, AND COMPETITIVE BENCHMARKS INFLUENCING MARKET POTENTIAL
 
 
 
 
 
 
 
13.1
INTRODUCTION
 
 
 
 
 
13.2
KEY PLAYERS STRATEGIES/ RIGHT TO WIN
 
 
 
 
 
13.3
REVENUE ANALYSIS, 2022–2024
 
 
 
 
 
 
13.4
MARKET SHARE ANALYSIS,
 
 
 
 
 
 
13.5
COMPANY EVALUATION MATRIX: KEY PLAYERS
 
 
 
 
 
 
 
13.5.1
STARS
 
 
 
 
 
13.5.2
EMERGING LEADERS
 
 
 
 
 
13.5.3
PERVASIVE PLAYERS
 
 
 
 
 
13.5.4
PARTICIPANTS
 
 
 
 
 
13.5.5
COMPANY FOOTPRINT: KEY PLAYERS,
 
 
 
 
 
 
13.5.5.1
COMPANY FOOTPRINT
 
 
 
 
 
13.5.5.2
REGION FOOTPRINT
 
 
 
 
 
13.5.5.3
PRODUCT FOOTPRINT
 
 
 
 
 
13.5.5.4
STERILITY TYPE FOOTPRINT
 
 
 
 
 
13.5.5.5
APPLICATION FOOTPRINT
 
 
 
13.6
COMPANY EVALUATION MATRIX: STARTUPS/SMES,
 
 
 
 
 
 
 
13.6.1
PROGRESSIVE COMPANIES
 
 
 
 
 
13.6.2
RESPONSIVE COMPANIES
 
 
 
 
 
13.6.3
DYNAMIC COMPANIES
 
 
 
 
 
13.6.4
STARTING BLOCKS
 
 
 
 
 
13.6.5
COMPETITIVE BENCHMARKING: STARTUPS/SMES,
 
 
 
 
 
 
13.6.5.1
DETAILED LIST OF KEY STARTUPS/ SMES
 
 
 
 
 
13.6.5.2
COMPETITIVE BENCHMARKING OF KEY STARTUPS/ SMES
 
 
 
13.7
COMPETITIVE SCENARIO
 
 
 
 
 
 
13.7.1
PRODUCT LAUNCHES
 
 
 
 
 
13.7.2
DEALS
 
 
 
 
 
13.7.3
OTHER DEVELOPMENTS
 
 
 
 
13.8
BRAND/PRODUCT COMPARATIVE ANALYSIS
 
 
 
 
 
13.9
VALUATION AND FINANCIAL METRICS
 
 
 
 
14
COMPANY PROFILES
 
 
 
 
 
 
14.1
KEY COMPANIES
 
 
 
 
 
 
14.1.1
BASF SE
 
 
 
 
 
14.1.2
CELANESE CORPORATION
 
 
 
 
 
14.1.3
CARPENTER TECHNOLOGY CORPORATION
 
 
 
 
 
14.1.4
AMETEK INC.
 
 
 
 
 
14.1.5
MITSUBISHI CHEMICAL GROUP CORPORATION
 
 
 
 
 
14.1.6
BERKELEY ADVANCED BIOMATERIALS
 
 
 
 
 
14.1.7
ZEUS COMPANY INC
 
 
 
 
 
14.1.8
COORSTEK INC
 
 
 
15
RESEARCH METHODOLOGY
 
 
 
 
 
 
15.1
RESEARCH DATA
 
 
 
 
 
 
15.1.1
SECONDARY DATA
 
 
 
 
 
 
15.1.1.1
KEY SOURCES OF SECONDARY DATA
 
 
 
 
 
15.1.1.2
KEY OBJECTIVES OF SECONDARY DATA
 
 
 
 
15.1.2
PRIMARY DATA
 
 
 
 
 
 
15.1.2.1
BREAKDOWN OF PRIMARY INTERVIEWS
 
 
 
 
 
15.1.2.2
KEY OBJECTIVES OF PRIMARY RESEARCH
 
 
 
15.2
MARKET SIZE ESTIMATION
 
 
 
 
 
 
15.2.1
ASIA PACIFIC BIOMATERIALS MARKET SIZE ESTIMATION
 
 
 
 
 
 
15.2.1.1
COMPANY REVENUE ANALYSIS (BOTTOM-UP APPROACH)
 
 
 
 
 
15.2.1.2
MNM REPOSITORY ANALYSIS
 
 
 
 
 
15.2.1.3
SECONDARY ANALYSIS
 
 
 
 
 
15.2.1.4
PRIMARY RESEARCH
 
 
 
 
 
 
15.2.1.4.1
INSIGHTS FROM PRIMARY EXPERTS
 
 
15.3
MARKET GROWTH RATE PROJECTIONS
 
 
 
 
 
15.4
DATA TRIANGULATION
 
 
 
 
 
15.6
RESEARCH ASSUMPTIONS
 
 
 
 
 
15.7
RESEARCH LIMITATIONS AND RISK ASSESSMENT
 
 
 
 
16
APPENDIX
 
 
 
 
 
 
16.1
DISCUSSION GUIDE
 
 
 
 
 
16.2
KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
 
 
 
 
 
16.3
AVAILABLE CUSTOMIZATIONS
 
 
 
 
 
16.4
RELATED REPORTS
 
 
 
 
 
16.5
AUTHOR DETAILS
 
 
 
 

Methodology

This study involved four major activities in estimating the current size of the Asia Pacific biomaterials market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. These findings, assumptions, and sizing were then validated with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate the market size of segments and subsegments.

Secondary Research

Secondary research was used mainly to identify and collect information for the extensive technical, market-oriented, and commercial study of the Asia Pacific biomaterials market. The secondary sources used for this study include the Journal of Biomedical Nanotechnology, Journal of Materials Science, Materials Science and Engineering, Journal of Biomedical Materials Research, Biomedical Engineering Society (BMES), Annual Reports, SEC Filings, Investor Presentations, Expert Interviews, and MarketsandMarkets Analysis. These sources were also used to obtain key information about major players, global product revenues, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives. Secondary data was collected and analyzed to arrive at the overall size of the global Asia Pacific biomaterials market, which was validated through primary research.

Primary Research

In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify the critical qualitative and quantitative information as well as assess future prospects of the market. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information.

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

The global size of the Asia Pacific biomaterials market was estimated through multiple approaches. A detailed market estimation approach was followed to estimate and validate the value of the market and other dependent submarkets. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • The major players in the industry and market have been identified through extensive primary and secondary research.
  • The product and company revenues generated from the Asia Pacific biomaterials business of players operating in the market have been determined through secondary research and primary analysis.
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.

Data Triangulation

After estimating the overall market size from the market size estimation process, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Market Definition

Biomaterials refer to substances that have been engineered to interact with biological systems for medical purposes. These materials are designed to be compatible with living tissues and can be used in various medical applications, such as implants, prosthetics, drug delivery systems, and tissue engineering. The primary goal of Asia Pacific biomaterials is to enhance or replace the function of a body part, promote healing, and improve overall health. These materials are selected and engineered based on their biocompatibility, mechanical properties, and ability to integrate seamlessly with the biological environment. Asia Pacific biomaterials play a crucial role in advancing medical technologies and improving patient outcomes.

Key Stakeholders

  • Biomaterial product manufacturing companies
  • Healthcare service providers (including hospitals & specialty clinics)
  • National and regional research boards and organizations
  • Research & development companies
  • Clinical research organizations (CROs)
  • Healthcare technology companies
  • Biotechnology companies
  • Research laboratories & academic institutes
  • Market research & consulting firms
  • Regulatory bodies

The main objectives of this study are as follows:

  • To define, describe, and forecast the Asia Pacific biomaterials market by type, application, and region
  • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
  • To analyze the micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall Asia Pacific biomaterials market
  • To analyze the opportunities for stakeholders and provide details of the competitive landscape for market leaders
  • To forecast the size of the market segments with respect to six regions: North America (US and Canada), Europe (Germany, France, the UK, Italy, Spain, and the Rest of Europe), Asia Pacific (Japan, China, India, South Korea, Australia, and the Rest of Asia Pacific), Latin America (Brazil, Mexico, Argentina, and the Rest of Latin America), the Middle East {GCC [Saudi Arabia (KSA), United Arab Emirates (UAE), and the Rest of GCC] and the Rest of Middle East}, and Africa
  • To profile the key players and analyze their market shares and core competencies2
  • To track and analyze competitive developments, such as product launches, partnerships, agreements, collaborations, and expansions
  • To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and product excellence strategy.
  • To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and product excellence strategy.

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report with additional efforts:

Product-Level Information

Country-wise Information:

  • Analysis for additional countries (up to five)

Company Information:

  • Detailed analysis and profiling of additional key market players across the globe

Personalize This Research

  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
Request A Free Customisation

Let Us Help You

  • What are the Known and Unknown Adjacencies Impacting the Asia Pacific Biomaterials Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
Customized Workshop Request

Custom Market Research Services

We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements

Get 10% Free Customisation

Growth opportunities and latent adjacency in Asia Pacific Biomaterials Market

DMCA.com Protection Status